Personalized medicine

Bioluminescence Ventures Reveals Partners and Investment Management Team

Retrieved on: 
Friday, January 5, 2024
Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Hospitals, Genetics, Science, Clinical Trials, Cardiology, Medical Supplies, Biology, Moores Cancer Center, Bank, Partner, OncoMed, Amgen, IND, Drug development, Biomedical engineering, Presidency College, Antibody, CFOS, CRA International, Spacecraft, Regenerative medicine, UC, Bank of America, Biomedical sciences, SVB Securities, Associate, BLV, University, University of California, Berkeley, Initial public offering, Venture, BMS, Electrical engineering, Genentech, UBS, Patient, Cell biology, Therapy, Economics, Biological engineering, Personalized medicine

Bioluminescence Ventures (“BLV”), a biotech venture firm investing in next-generation medicines, today revealed its initial team of Partners, whose collective experience and expertise spans preclinical research, translational science, clinical development, medical affairs, regulatory, commercial strategy, business development, and strategic investment banking functions across therapeutic areas.

Key Points: 
  • Bioluminescence Ventures (“BLV”), a biotech venture firm investing in next-generation medicines, today revealed its initial team of Partners, whose collective experience and expertise spans preclinical research, translational science, clinical development, medical affairs, regulatory, commercial strategy, business development, and strategic investment banking functions across therapeutic areas.
  • Every day, I feel honored and lucky to be working with such talented, mission-driven, and caring people.”
    Chloe Kim, Ph.D. joined Bioluminescence Ventures as a Partner in 2022.
  • Negin Mokhtari, Ph.D. joined Bioluminescence Ventures as a Partner in 2023 and brings a blend of scientific expertise, operational experience, and investment skills to the firm.
  • Prior to joining Bioluminescence Ventures, Dr. Mokhtari was part of the investment team at Genoa Ventures, focusing on the convergence of biology and technology, and serving on the board of multiple companies.

Blue Spark Technologies Adds MaryAnne Rizk to Board of Advisors

Retrieved on: 
Thursday, January 4, 2024
RWD, CVS, Drug development, FDA, Health, DHT, Record, Heart, RPM, Temperature, Knowledge, DCT, Merck, Organization, Vital signs, Personalized medicine, Medical device

CLEVELAND, Jan. 4, 2024 /PRNewswire/ -- Blue Spark Technologies, Inc., a proven innovative digital health technology (DHT) leader in enabling AI-powered remote patient monitoring (RPM) to support precision patient-centric drug development, proudly announces the appointment of Dr. MaryAnne Rizk, a recognized leader in drug development technological innovation, to the Company's advisory board.

Key Points: 
  • Dr. Rizk will work with Blue Spark Technologies to identify the evolution of its integrated growth.
  • "We are incredibly fortunate to welcome Dr. Rizk to our advisory board," said John Gannon, President and CEO of Blue Spark Technologies.
  • I am confident that the collective expertise of our board will further propel Blue Spark Technologies to new heights of success."
  • "I am thrilled to be appointed to the Board of Advisors for Blue Spark Technologies," stated Dr. Rizk.

Novel Genetic Priority Score Unveiled to Enhance Target Prioritization in Drug Development

Retrieved on: 
Wednesday, January 3, 2024
Leducq Foundation, DOI, Drug discovery, Drug development, GPS, MD, Doctor of Philosophy, ANR, Personalized medicine, Nature Genetics, Gene, Lung, NIH, Therapy, Cardiff University, Algorithm, Foundation (nonprofit), Vaccine

NEW YORK, Jan. 3, 2024 /PRNewswire-PRWeb/ -- Driven by the need for a better way to prioritize targets for drug development, the Icahn School of Medicine at Mount Sinai has led the development of a novel "genetic priority score" (GPS) that will integrate various types of human genetic data into a single easy-to-interpret score.

Key Points: 
  • The score measures the general ability of a gene to be targeted by drugs; genes with a high score in the new tool are more likely to succeed as a drug target.
  • The score identifies both known drug gene targets as well as potential novel therapeutic targets.
  • The GPS, with its potential to streamline target prioritization, is positioned to have a significant impact on drug development.
  • The paper is titled "Development of a human genetics-guided priority score for 19,365 genes and 399 drug indications."

Nucleic Acid Isolation and Purification (Genomic DNA, Plasmid DNA, mRNA) Market Research - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 3, 2024
Other Science, Science, RNA, Kits, Drug discovery, Biotechnology, Agriculture, Gene expression profiling, Messenger, Research, DNA, Region, MicroRNA, Personalized medicine, USD, Genomics, ChromeOS, Diagnosis, Growth, Patient, NAIP, Automation, Vaccine

In 2022, the kits segment accounted for the largest share of the global nucleic acid isolation and purification market.

Key Points: 
  • In 2022, the kits segment accounted for the largest share of the global nucleic acid isolation and purification market.
  • In 2022, the kits segment accounted for the largest share of the global nucleic acid isolation and purification market.
  • Based on type, the global nucleic acid isolation and purification market is segmented into plasmid DNA, total RNA, circulating nucleic acid, genomic DNA, messenger RNA, microRNA, and other nucleic acid isolation and purification types.
  • In 2022, the plasmid DNA isolation and purification segment dominated the global nucleic acid isolation and purification market.

Molecular Cytogenetics Market Size, Share & Trends Analysis Report 2023-2030 - A $4.46 billion by 2030, with CAGR of 10.6% from 2023 to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 28, 2023
Biotechnology, Pharmaceutical, Oncology, Health, Infectious Diseases, Hospitals, Genetics, Clinical Trials, AIR, NGS, Down syndrome, WHO, Cystic fibrosis, Incidence, Thermo Fisher Scientific, DSM-IV codes, Personalized medicine, USD, Knowledge, COVID-19, Public, Cytogenetics, Genomics, CGH, Growth, FISH

The global molecular cytogenetics market size is anticipated to reach USD 4.46 billion by 2030.

Key Points: 
  • The global molecular cytogenetics market size is anticipated to reach USD 4.46 billion by 2030.
  • The market is expected to expand at a CAGR of 10.6% from 2023 to 2030.
  • Thus, the high incidence of diagnostic testing during the pandemic has fueled the growth of the market for molecular cytogenetics.
  • Moreover, rising strategic initiatives by operating players for technological advancements in cytogenetic tools are projected to propel the market for molecular cytogenetics.

Genetic Testing's Role in Personalized Medicine and Targeted Therapies for Respiratory Conditions - ResearchAndMarkets.com

Retrieved on: 
Monday, December 18, 2023
Health, Genetics, Personalized medicine, COPD, Genome-wide association study, Disorder, Prevalence, Granulomatous–lymphocytic interstitial lung disease, Privacy, Risk, Diagnosis, GWAS, Respiratory disease, Marker beacon, Region, Genetic testing, Health information management, Growth, Chronic obstructive pulmonary disease, Asthma, Cystic fibrosis, Agriculture, Pharmaceutical industry, Vaccine, Medical device

Genetic testing has emerged as a crucial tool for understanding the genetic underpinnings of various respiratory conditions.

Key Points: 
  • Genetic testing has emerged as a crucial tool for understanding the genetic underpinnings of various respiratory conditions.
  • Factors contributing to this growth include the rising prevalence of respiratory diseases, advances in genetic testing technologies, and increasing awareness of personalized medicine.
  • Personalized Medicine: Genetic testing allows healthcare providers to tailor treatment plans to an individual's genetic profile, enhancing treatment efficacy and minimizing adverse effects.
  • Targeted Therapies: Genetic testing results are guiding the development of targeted therapies for specific respiratory diseases, leading to more effective and precise treatment options.

Global High Resolution Melting Research Report 2023: Market to Reach $385.6 Billion by 2030 - Clinical Diagnostics be the Fastest-growing Segment - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 13, 2023
Health, Technology, Other Technology, Other Health, Other Science, Science, Zygosity, COPD, Conditional sentence, Prevalence, Barack Obama, Genomics, Patient, DSM-IV codes, FDA, USD, QPCR, Genetic testing, Personalized medicine, Anti-transglutaminase antibodies, HIV, Cancer, HRM, Neoplasm, Mutation, Overalls, Cystic fibrosis, Vaccine, Pharmaceutical industry, Software

The "High Resolution Melting Analysis Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents, Software), By Application (Mutation Scanning, Zygosity Testing), By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "High Resolution Melting Analysis Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents, Software), By Application (Mutation Scanning, Zygosity Testing), By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global high resolution melting analysis market size is expected to reach USD 385.6 billion by 2030, growing at a CAGR of 3.32% from 2023 to 2030
    Increasing incidences of cancer, sickle cell anemia, HIV and other STDs are expected to positively reinforce demand for smart and simple molecular diagnostics.
  • Recent developments in the field of QPCR, next generation sequencing, genomics and big data analytics have been instrumental in strengthening the precision medicine approach.
  • The drug kalydeco was approved for patients reported to have a specific genetic mutation known as "G551D mutation.

Precision Medicine Research Report 2023: Diagnostics, Genetic Tests, Esoteric Tests, Therapeutics, Pharmaceuticals, Medical Devices - Global Market to Reach $160 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 13, 2023
Health, Pharmaceutical, Diagnosis, Prevalence, Therapy, Whole genome sequencing, Human, Medical device, Human genome, Patient, Medicine, Neurology, Personalized medicine, Cancer, Test management, Growth, NGS, Biomarker, Medication, Government, Big data, Vaccine, Pharmaceutical industry

The "Precision Medicine Market Size, Share & Trends Analysis Report By Application ((Diagnostics (Genetic Tests, Esoteric Tests), Therapeutics (Pharmaceuticals, Medical Devices)), By End Use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Precision Medicine Market Size, Share & Trends Analysis Report By Application ((Diagnostics (Genetic Tests, Esoteric Tests), Therapeutics (Pharmaceuticals, Medical Devices)), By End Use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The Human Genome Project introduced some marvelous cutting-edge techniques such as whole genome sequencing and targeted sequencing.
  • These technologies are being used by researchers for the study of genomes and creation of personalized therapies for treatment of various illnesses.
  • The diagnostic and therapeutic precision medicine market thus holds immense potential and is quickly turning into a fundamental segment of patient care.

Beyond Medtech: Healthcare+ Expo Taiwan Sets New Stage for Global Innovation in Future AI Healthcare

Retrieved on: 
Friday, December 1, 2023
Technology, Health, Finance, Healthcare Reform, Public Policy, Government, Professional Services, Artificial Intelligence, Telecommunications, Medical Devices, General Health, Internet, Hardware, Semiconductor, Data Management, Multimedia, Cancer, Intel, Personalized medicine, Taipei Nangang Exhibition Center, Growth, Hospital, AI, Microsoft, Czech Republic, Expo

The Healthcare+ Expo Taiwan, currently taking place at Nangang Exhibition Hall 1 from November 30 to December 3, 2023, is poised to redefine the landscape of AI healthcare on a global scale.

Key Points: 
  • The Healthcare+ Expo Taiwan, currently taking place at Nangang Exhibition Hall 1 from November 30 to December 3, 2023, is poised to redefine the landscape of AI healthcare on a global scale.
  • View the full release here: https://www.businesswire.com/news/home/20231201062013/en/
    Expand businesses into growing markets in the APAC region with Healthcare+ Expo Taiwan.
  • This proficiency positions Taiwan as a key player in driving substantial computing power, establishing it as an indispensable global collaborator in the realm of AI healthcare.
  • The Healthcare+ Expo 2024 is scheduled for December 5 to 8, 2024, and will continue to serve as a catalyst for transformative advancements and collaborative breakthroughs in the ever-evolving landscape of AI healthcare.

Genome Insight to Unveil Hong Kong Real-World Evidence on Target Enhanced Whole Genome Sequencing at 2023 AACR-KCA Joint Conference

Retrieved on: 
Friday, November 17, 2023
Science, Biotechnology, Research, Oncology, Health, Data Management, Technology, Genetics, TMB, GCN, Multimedia, Whole genome sequencing, Personalized medicine, Conference, Treatment of lung cancer, Diagnosis, MET, Insight, NGS, Biomarker, Poster, AACR, NSCLC, Antibiotics, Cancer, Hong Kong

Genome Insight, a precision healthcare solutions company advancing whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease, will announce new-real-world evidence from Hong Kong on the application of Target Enhanced Whole Genome Sequencing (TE-WGS) at the 2023 AACR-KCA joint conference on Precision Medicine in Cancer in Seoul, Korea.

Key Points: 
  • Genome Insight, a precision healthcare solutions company advancing whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease, will announce new-real-world evidence from Hong Kong on the application of Target Enhanced Whole Genome Sequencing (TE-WGS) at the 2023 AACR-KCA joint conference on Precision Medicine in Cancer in Seoul, Korea.
  • (Photo: Business Wire)
    Genome Insight's presentation will feature the outcomes of a collaborative real-world evidence program on TE-WGS in lung cancers.
  • Genome Insight will present the case of a 78-year-old Asian man from Hong Kong with poorly differentiated Non-Small Cell Lung Cancer (NSCLC).
  • "We are thrilled to present this real-world evidence from Hong Kong at the esteemed 2023 AACR-KCA Joint Conference," said Ryul Kim, Chief Technology Officer.